Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GLUCOPHAGE Bristol-Myers Squibb · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC |
| 2 | EXPERIMENTAL | Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC |
| 3 | ACTIVE_COMPARATOR | GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb |
| 4 | ACTIVE_COMPARATOR | GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb |
| Name | Type | Description |
|---|---|---|
| Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC | DRUG | - |
| GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
GLUCOPHAGE Bristol-Myers Squibb is used for Type II Diabetes. It is a small molecule in the metabolic therapeutic area. The clinical program recorded for this asset includes one completed Phase 1 trial conducted in healthy volunteers aged 19 years and older.
Novartis AG, which trades under the ticker NVS, is the developer of GLUCOPHAGE Bristol-Myers Squibb. The asset is listed in the metabolic therapeutic area for Type II Diabetes, and the development program recorded for it consists of a single Phase 1 trial.
GLUCOPHAGE Bristol-Myers Squibb is in Phase 1 development. The program includes one Phase 1 trial, which is completed, with no active trials currently recorded. The study was randomized and active controlled, and it enrolled 16 participants.
GLUCOPHAGE Bristol-Myers Squibb has been studied in trial NCT00882882, titled a study to demonstrate the relative bioavailability of metformin HCL 500 mg extended release tablets under fasting conditions. That Phase 1 trial is completed, enrolled 16 participants, was randomized and active controlled, and included healthy volunteers.